The New Hampshire Supreme Court recently issued a ruling in a significant case involving Advent Medical Products, Inc. and its founder Randall Fincke. The court's decision addressed allegations of securities violations against the company, which affected thirteen investors who purchased securities from Advent. The ruling is crucial as it clarifies the responsibilities of companies in disclosing material facts to investors and the consequences of failing to register securities.
In the case, known as Appeal of Advent Medical Products, Inc. (Docket No. 2024-0720), the New Hampshire Bureau of Securities Regulation had previously found Advent and Fincke liable for violating the state's Uniform Securities Act. The Bureau alleged that the company sold unregistered securities and misrepresented material facts to investors between 2010 and 2016. The court's ruling was issued on July 31, 2026, after hearing arguments on April 7, 2026.
Background
Advent Medical Products, Inc. was founded by Randall Fincke in 2004 to develop and manufacture defibrillators. The company faced several challenges in bringing its products to market, including regulatory hurdles from the FDA and issues with product defects. From 2012 to 2017, Advent sought investments to support its operations, primarily through Fincke's brother, Gary Fincke, who solicited investors in New Hampshire.
Despite selling several securities, Advent failed to register them with the New Hampshire Bureau of Securities Regulation as required by law. In 2023, the Bureau filed a petition alleging that Advent and Fincke had violated the state's securities laws by selling unregistered securities and making misrepresentations to investors. Following an administrative hearing, the Bureau's director issued an order imposing significant penalties on the respondents, including fines and a cease-and-desist order.
The Ruling
The New Hampshire Supreme Court reviewed the Bureau's findings and the director's orders. The court affirmed some aspects of the Bureau's ruling but reversed others. The court found that the director had erred in determining that the respondents had unlawfully misrepresented material facts to investors regarding Fincke's prior legal issues and the timeline for bringing products to market.
The court ruled, "The respondents’ failure to disclose two lawsuits involving Fincke rendered materially misleading the information they did give investors regarding ‘Fincke’s biography and history in the defibrillation market.'"
However, the court also stated that the respondents did not make false representations about the timeline for marketing their defibrillators, as the evidence indicated that they were discussing the entire product line, not just the AEDs that faced regulatory delays.
Additionally, the court addressed the issue of whether the sales of securities were exempt from registration under state law. The court found that the director had misapplied the law regarding the number of purchasers and the exemptions available to Advent, leading to a remand for further findings on these issues.
Impact
This ruling has significant implications for both Advent Medical Products and the broader business community in New Hampshire. By clarifying the standards for misrepresentation and the requirements for registering securities, the court's decision reinforces the importance of transparency and accountability in corporate practices.
The ruling also highlights the need for companies to be diligent in their disclosures to investors, particularly regarding any legal issues that could affect their credibility. This case serves as a reminder to businesses about the potential consequences of failing to comply with securities regulations.
What's Next
The case has been sent back to the Bureau for further proceedings to determine the applicability of the registration exemptions for the securities sold by Advent. The Bureau will need to reassess the facts surrounding the sales and the penalties imposed. Additionally, the respondents may consider their options for further appeals depending on the outcomes of the remanded proceedings.